Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways - PubMed (original) (raw)
. 2012 Mar 1;442(2):293-302.
doi: 10.1042/BJ20110282.
Affiliations
- PMID: 21999204
- DOI: 10.1042/BJ20110282
Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways
Ming-Cheng Chang et al. Biochem J. 2012.
Abstract
Ovarian cancer has one of the highest mortalities in malignancies in women, but little is known of its tumour progression properties and there is still no effective molecule that can monitor its growth or therapeutic responses. MSLN (mesothelin), a secreted protein that is overexpressed in ovarian cancer tissues with a poor clinical outcome, has been previously identified to activate PI3K (phosphoinositide 3-kinase)/Akt signalling and inhibit paclitaxel-induced apoptosis. The present study investigates the correlation between MSLN and MMP (matrix metalloproteinase)-7 in the progression of ovarian cancer, and the mechanism of MSLN in enhancing ovarian cancer invasion. The expression of MSLN correlated well with MMP-7 expression in human ovarian cancer tissues. Overexpressing MSLN or ovarian cancer cells treated with MSLN showed enhanced migration and invasion of cancer cells through the induction of MMP-7. MSLN regulated the expression of MMP-7 through the ERK (extracellular-signal-regulated kinase) 1/2, Akt and JNK (c-Jun N-terminal kinase) pathways. The expression of MMP-7 and the migrating ability of MSLN-treated ovarian cancer cells were suppressed by ERK1/2- or JNK-specific inhibitors, or a decoy AP-1 (activator protein 1) oligonucleotide in in vitro experiments, whereas in vivo animal experiments also demonstrated that mice treated with MAPK (mitogen-activated protein kinase)/ERK- or JNK-specific inhibitors could decrease intratumour MMP-7 expression, delay tumour growth and extend the survival of the mice. In conclusion, MSLN enhances ovarian cancer invasion by MMP-7 expression through the MAPK/ERK and JNK signal transduction pathways. Blocking the MSLN-related pathway could be a potential strategy for inhibiting the growth of ovarian cancer.
Similar articles
- Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway.
Chang MC, Chen CA, Hsieh CY, Lee CN, Su YN, Hu YH, Cheng WF. Chang MC, et al. Biochem J. 2009 Dec 10;424(3):449-58. doi: 10.1042/BJ20082196. Biochem J. 2009. PMID: 19747165 - Kalopanaxsaponin A inhibits PMA-induced invasion by reducing matrix metalloproteinase-9 via PI3K/Akt- and PKCdelta-mediated signaling in MCF-7 human breast cancer cells.
Park SK, Hwang YS, Park KK, Park HJ, Seo JY, Chung WY. Park SK, et al. Carcinogenesis. 2009 Jul;30(7):1225-33. doi: 10.1093/carcin/bgp111. Epub 2009 May 6. Carcinogenesis. 2009. PMID: 19420016 - Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment.
Coelho R, Marcos-Silva L, Ricardo S, Ponte F, Costa A, Lopes JM, David L. Coelho R, et al. Expert Rev Anticancer Ther. 2018 Feb;18(2):177-186. doi: 10.1080/14737140.2018.1418326. Epub 2017 Dec 21. Expert Rev Anticancer Ther. 2018. PMID: 29241375 Review. - The Jun N-terminal kinases signaling pathway plays a "seesaw" role in ovarian carcinoma: a molecular aspect.
Dou Y, Jiang X, Xie H, He J, Xiao S. Dou Y, et al. J Ovarian Res. 2019 Oct 21;12(1):99. doi: 10.1186/s13048-019-0573-6. J Ovarian Res. 2019. PMID: 31639019 Free PMC article. Review.
Cited by
- Novel 3,6-Disubstituted Pyridazine Derivatives Targeting JNK1 Pathway: Scaffold Hopping and Hybridization-Based Design, Synthesis, Molecular Modeling, and In Vitro and In Vivo Anticancer Evaluation.
Shaalan MM, Osman EEA, Attia YM, Hammam OA, George RF, Naguib BH. Shaalan MM, et al. ACS Omega. 2024 Aug 19;9(35):37310-37329. doi: 10.1021/acsomega.4c05250. eCollection 2024 Sep 3. ACS Omega. 2024. PMID: 39246493 Free PMC article. - Mesothelin promotes brain metastasis of non-small cell lung cancer by activating MET.
Xia S, Duan W, Xu M, Li M, Tang M, Wei S, Lin M, Li E, Liu W, Wang Q. Xia S, et al. J Exp Clin Cancer Res. 2024 Apr 3;43(1):103. doi: 10.1186/s13046-024-03015-w. J Exp Clin Cancer Res. 2024. PMID: 38570866 Free PMC article. - Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology.
Kembuan GJ, Kim JY, Maus MV, Jan M. Kembuan GJ, et al. Trends Cancer. 2024 Apr;10(4):312-331. doi: 10.1016/j.trecan.2024.01.003. Epub 2024 Feb 13. Trends Cancer. 2024. PMID: 38355356 Review. - Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.
Bahar ME, Kim HJ, Kim DR. Bahar ME, et al. Signal Transduct Target Ther. 2023 Dec 18;8(1):455. doi: 10.1038/s41392-023-01705-z. Signal Transduct Target Ther. 2023. PMID: 38105263 Free PMC article. Review. - Multi-Functional Regulation by YAP/TAZ Signaling Networks in Tumor Progression and Metastasis.
Thrash HL, Pendergast AM. Thrash HL, et al. Cancers (Basel). 2023 Sep 24;15(19):4701. doi: 10.3390/cancers15194701. Cancers (Basel). 2023. PMID: 37835395 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous